Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) EPS (Weighted Average and Diluted) (2021 - 2025)

Prime Medicine filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.24 for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 22.58% to -$0.24 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.37, a 16.97% increase, with the full-year FY2025 number at -$1.35, up 18.18% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.24 in Q4 2025 for Prime Medicine, up from -$0.32 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.72 in Q4 2022 to a low of -$4.45 in Q4 2021.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.45 (2023), compared with a mean of -$0.86.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 116.18% in 2022 and later tumbled 200.0% in 2023.
  • Prime Medicine's EPS (Weighted Average and Diluted) stood at -$4.45 in 2021, then soared by 116.18% to $0.72 in 2022, then tumbled by 200.0% to -$0.72 in 2023, then soared by 56.94% to -$0.31 in 2024, then rose by 22.58% to -$0.24 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.24 (Q4 2025), -$0.32 (Q3 2025), and -$0.41 (Q2 2025) per Business Quant data.